The Business, Energy and Industrial Strategy Committee of the House of Commons have today (Thursday) published a report on the potential impact on Britain’s pharmaceutical industry if the UK leaves the European Union.
The report warns of both a negative economic impact and that leaving the EU and European Medicines Agency could damage access to new treatments for people in Britain.
Commenting, Gareth Thomas MP, leading supporter of the People's Vote campaign, said:
“Today’s report by the Business, Energy and Industrial Strategy committee on Brexit and the pharmaceutical industry should set alarm bells ringing across Government.
“The report notes that a no deal scenario would not only have a huge economic cost, it would also jeopardize patients’ access to medicines, with nearly 75% of pharmaceutical imports into this country coming from elsewhere in the EU.
“The report also makes it clear that those who think staying in the Customs Union alone will protect jobs and services are plain wrong. Leaving the European Medicines Agency will damage the ability of the UK to access medical innovations and is a threat to the success of the NHS.
“Protecting the NHS, securing jobs and investment and delivering the best treatment for patients are all threatened by Brexit. That is why so many who work in the NHS are demanding a People’s Vote on the final Brexit deal.”
Notes to editors
The Committee’s report can be read here: https://www.parliament.uk/business/committees/committees-a-z/commons-select/business-energy-industrial-strategy/news-parliament-2017/pharmaceutical-report-published-17-19/